Many therapeutic efforts with Ab–NPs focus on cancer and on improving survival in vivo, by targeting EGFR [104], CD44 [105], mucin 1 C terminus [106], HER2 [107] (which are overexpressed in a variety of cancers such as breast and lung cancers), and death receptor 5 [108] (which are overexpressed in pancreatic cancer). This evidence concerns the gene ERBB2 and cancer.